Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study

Fuchs M, Goergen H, Kobe C, Kuhnert G, Hitz F, Greil R, Sasse S, Topp MS, Schaefer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause S, Wilhelm M, Maschmeyer G, Thiemer J, Duehrsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, Von Tresckow B, Dietlein M, Borchmann P, Engert A (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Publisher: KARGER

City/Town: BASEL

Pages Range: 297-297

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Involved external institutions

Paracelsus Medizinische Privatuniversität Austria (AT) Universitätsklinikum Münster Germany (DE) Kantonsspital St.Gallen Switzerland (CH) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Köln Germany (DE) Klinikum Nürnberg Germany (DE) Klinikum rechts der Isar Germany (DE) Klinikum Ernst von Bergmann Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) Germany (DE) Universitätsklinikum Tübingen Germany (DE) Klinikverbund Bremen (Gesundheit Nord) Germany (DE) Vrije Universiteit Amsterdam (VU) / University Amsterdam Netherlands (NL) Universitätsklinikum Essen Germany (DE) Onkologische Schwerpunktpraxis Bielefeld Germany (DE) Universitätsklinikum Regensburg Germany (DE) Universitätsklinikum Würzburg Germany (DE) Julius-Maximilians-Universität Würzburg Germany (DE) Universitätsklinikum Ulm Germany (DE)

How to cite

APA:

Fuchs, M., Goergen, H., Kobe, C., Kuhnert, G., Hitz, F., Greil, R.,... Engert, A. (2019). Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study. In ONCOLOGY RESEARCH AND TREATMENT (pp. 297-297). BASEL: KARGER.

MLA:

Fuchs, M., et al. "Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2019. 297-297.

BibTeX: Download